---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-005715"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T20:29:28.177996+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dermata shareholders approve reverse stock split (1:5-1:30) and equity plan expansion

## Summary
- Stockholders approved reverse stock split at ratio from 1:5 to 1:30, exact ratio to be set by Board.
- Equity plan amended to increase share reserve from 629,069 to 1,198,951 and raise annual evergreen to 5%.
- Three Class III directors elected: Proehl, Wierenga, and Scott.
- Ratified Moss Adams LLP as auditor for FY2024.
- Adjournment proposal also approved.

## SEC filing metadata
- accession: 0001654954-24-005715
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495424005715/0001654954-24-005715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495424005715/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-005715
- JSON: https://secwatch.observer/filing/0001654954-24-005715.json
- Plain text: https://secwatch.observer/filing/0001654954-24-005715.txt

## Key facts
- Shareholder Votes
  Dermata Therapeutics, Inc. shareholders approved Election of three Class III directors.
  - Proposal: director election
  - Outcome: passed
  source text: The matters voted on at the Annual Meeting were: (1) the election of three Class III directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495424005715/0001654954-24-005715-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.